pemafibrate
Jump to navigation
Jump to search
Indications
Clinical significance
- does not lower incidence of cardiovascular events
Mechanism of action
- selective peroxisome proliferator-activated receptor alpha modulator
- reduces triglyceride levels
- improves other lipid levels
More general terms
References
- ↑ Boswoth T Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial. Twenty-Five Percent Reduction Has No Effect. Medscape. Nov 5, 2022 https://www.medscape.com/viewarticle/983610
Das Pradhan A et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 2022 Nov 5; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36342113 https://www.nejm.org/doi/10.1056/NEJMoa2210645